life scienc tool diagnost
reason report
slower growth lower guid confirm uncertain
bottom line remain market perform view
compani still inadequ posit growth biolog
despit recent bioaccord launch emerg standard
biomolecular analysi close tie competitor
product competit product rapidli gain
traction drug develop head toward stronghold
qa/qc long-term deliv appear y/i organ
growth vs number street org growth estim
driven weak industri academ segment lc-
ms divis deliv organ growth thermal analysi
ta divis flat organ sale pharma market
core still deliv instrument flat like
highlight challeng sale forc reorgan continu
impact growth europ also came softer declin y/i
org growth asia deliv org result contrast
earlier peer group print quarter also lower full-year
organ revenu growth guid vs y/i number
believ challeng uniqu associ
limit read-through peer compani appear
deliv industri averag expect link
op deliv growth respect lc-m
segment think result reflect weak
across lc-m industri overal like continu share loss
would agre comparison like get challeng
earlier sale forc reorgan limit posit
biomolecul grow concern us reflect
weak instrument overal sale believ instrument sale
indic challeng ahead stem sale forc
organ conduct last year believ
impact lack sale forc effect like continu
instrument sale lead indic consum pull-through
ahead look detail call around mass spec lc
report revenues/ep vs
 street estim organ revenu growth
y/i vs our/street estim soft demand
driven weaker sale industri asia china europ
academic/govern busi also lower guidanc
organ growth ep guidanc also lower
question call believ investor like focu
overal challeng instrument sale larg associ
industri lc-m divis despit new product launch asm
pleas refer page import disclosur price chart analyst certif
launch new bioaccord uptak recent launch
bioaccord expect see instrument gain
traction biopharma qa/qc continu build
manag bench retir key leadership last
year includ recent retir challeng europ china
dollar thousand except ep
interest/ expens
revenu bp
compani report svb leerink estim
puneet souda certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori water corpor
leerink suspend coverag juli
creat bluematrix
pt reflect ev/ebitda multipl line ev/ebitda lst multipl
share current trade line tool averag believ would warrant higher
multipl sale rep reach full product help drive lc-m growth biopharma market still
believ offer premium product potenti return growth sale rep new mass spec
product challeng launch bioaccord address meet biotherapeut need market deriv
price target appli averag ev/ebitda multipl compris life scienc peer group
risk valuat
primari risk price target includ
could acceler stock repurchas help drive stock higher one could also envis biopharma
uptick drive equival revenu growth across competitor uptick biopharmaceut fund
could pose risk know market remain healthi
fda approv process directli impact biopharma biotech compani could continu favor
older method continu domin biopharma drug sale could continu acceler result
acceler spend current level revenu deriv biopharma
uptick spend biopharma like increas revenu
acceler global budget research could caus upsid risk forecast expand budget
govern academ fund could result higher revenu rel estim
signific academ exposur revenu ww nih exposur less revenu pickup
academ spend could headwind rate estim increas global budget could
result shift focu strategi growth could increas oper risk
emerg market pose signific upsid risk view despit signific growth china far
acceler uptak product could impact view sudden macroeconom chang lead increas
fund fund could impact posit china repres compani revenu
chang regul lead easier oper china foreign compani like benefit well
given posit market
high attach rate integr part busi model despit entri high resolut mass
spec lc could continu remain demand drive sale higher estim could continu
maintain legaci high attach rate lc system due requir technolog competit
chang market
fda regul remain paramount affect adopt rate clinic diagnost tool clinic
diagnost remain major growth area futur chang regul restrict use mass
spectromet clinic diagnost laboratori could also improv compani prospect restrict could
affect growth adopt rate certain tool regul would also increas cost complianc test
rate price target histori thermo fisher scientif inc
leerink suspend coverag juli
creat bluematrix
share current trade ev/ebitda slightli large- mid-cap tool
averag ev/ebitda given impress growth deliv
leverag biolog drug discoveri develop product china emerg market tailwind still
continu believ continu hold posit lead lab tool suppli provid
like continu post strong growth expect trade line large- mid-cap tool averag
deliv ev/ebitda deriv price target appli multipl ebitda
estim
risk valuat
primari risk price target includ
slowdown global budget research could caus downsid risk forecast tighten budget
govern academ fund could result lower revenu rel estim furthermor
restrict global budget could result shift focu strategi growth could increas oper risk
declin government spend could risk downsid forecast growth nih spend
biopharma declin pose greatest risk tmo revenu declin biopharma fund could highli impact
revenu given third revenu lever biopharma industri slowdown biopharma fund
would result downsid risk estim valuat biomolecul forecast ramp drug
market mid-teen estim hing prolifer drive use tmo bioprocess
equip mass spectromet instrument reagent character molecul
scale diversif could backfir tmo size diversif advantag compani
consolid space pose signific challeng term move needl growth perspect given
size acquisit alreadi done includ life pthn transact would ventur
estim deal size least grow north organ make signific move
market although asset might visibl street given limit public asset larg
number privat asset could potenti avail howev pose risk street might
appreci capabl asset enough move needl
emerg market pose signific risk tmo revenu geopolit risk emerg market could
disrupt oper downsid risk valuat forecast risk could countri region specif
could also impact tmo strategi creat higher barrier entri exist futur market local product
reagent prefer import oper numer intern market includ
india china eastern europ name
tmo exposur china could also pose concentr risk china repres tmo revenu
macroeconom impact chines market could lead declin compani revenu regul chines
polici could also caus restrict oper lead lower activ china question remain china
relat detail headwind could emerg polici risk
 synergi may go plan tmo acquisit sizabl may go plan
could result integr risk lower-than-expect synergi integr requir cultur
process adapt synergi model forecast risk estim remain integr
unquantifi aspect target forecast model margin eros could
occur under-perform acquisit
increas risk amazon distribut busi like impact revenu tmo laboratori
product servic lp busi custom shown will consid amazon vendor
consum product expir date beaker pipett expect amazon
expertis logist suppli chain allow amazon offer product competit cost thu impact lp
revenu overal busi
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
